Abstract: The present invention relates to: a substituted thiazolidinedione derivative compound having a novel structure acting as a sterol regulatory element-binding protein-1 (SREBP1) inhibitor, a hydrate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating cancer, comprising same as an active ingredient.

Abstract: The present disclosure relates to a novel peptide derivative, etc., the peptide derivative being a partially modified adiponectin receptor peptide which, compared to conventional adiponectin receptor peptides, has higher stability, superior p-AMPK activity, and improved physical properties and activity and thus offers advantages when formulated into a drug. Therefore, the peptide derivative of the present invention can be used to prevent or treat inflammatory skin diseases, wounds, hair loss, fibrosis, metabolic diseases, or cancer, to prevent or alleviate aging, sensitive skin, or wrinkles, or to enhance moisturization.

Abstract: The present invention relates to a novel peptoid derivative and the like. The peptoid derivative is obtained by partially modifying an adiponectin receptor peptide, and has high stability and excellent p-AMPK activity, compared to existing adiponectin receptor peptides and has improved physical properties and activity, thus having the advantage of being suitable for drug formulation. Therefore, the peptoid derivative of the present invention can be used for the prevention or treatment of skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, or cancer, or the prevention or amelioration of aging, sensitive skin, wrinkles, or moisturization.

Abstract: The present invention relates to a compound comprising an EZH2 inhibitor and an E3 ligase binder, and a pharmaceutical composition for preventing or treating EZH2-associated disease and a pharmaceutical composition for selective protein degradation containing the same as an active ingredient. Since the compound of the present invention can selectively degrade EZH2, it can be effectively used for the treatment of EZH2-related diseases and cancers, particularly, cancers in which EZH2 is overexpressed, and can be usefully used for the selective degradation of EZH2.